Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
BCG is currently the only licensed vaccine against tuberculosis (TB) and confers protection against meningitis and miliary tuberculosis in infants, although pulmonary disease protection in adults is inconsistent. Recently, promising HIV-1 immunogens were developed, such as the T-cell immunogens “tHI...
Main Authors: | Athina Kilpeläinen, Narcís Saubi, Núria Guitart, Nathifa Moyo, Edmund G. Wee, Krupa Ravi, Tomáš Hanke, Joan Joseph |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00923/full |
Similar Items
-
Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
by: Athina Kilpeläinen, et al.
Published: (2019-08-01) -
Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
by: Narcís Saubi, et al.
Published: (2020-11-01) -
Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned
by: Athina Kilpeläinen, et al.
Published: (2018-11-01) -
Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice
by: Monalisa Martins Trentini, et al.
Published: (2022-08-01) -
Recombinant BCG to Enhance Its Immunomodulatory Activities
by: Magdalena Kowalewicz-Kulbat, et al.
Published: (2022-05-01)